<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03675412</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#18-729</org_study_id>
    <nct_id>NCT03675412</nct_id>
  </id_info>
  <brief_title>Caffeine Consumption in Glaucoma Patients and Healthy Subjects</brief_title>
  <official_title>Acute Changes in Optic Nerve Head (ONH) and Macular Blood Flow After Caffeine Consumption in Glaucoma Patients and Healthy Subjects: A Quantitative Optic Coherence Tomography Angiography (OCTA) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wills Eye</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wills Eye</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Caffeine is the most widely consumed drinking nutrient in the world. Caffeine effects various
      organs and the vascular system. It decreases ocular blood flow due to vasoconstriction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ingestion of caffeine in glaucoma patients and healthy subjects may decrease peripapillary
      and macular blood flow in the back of the eye.

      The primary objective of this study is to assess the acute changes in peripapillary and
      macular blood flow before and after an intake of oral caffeine (200 milligram tablet) in
      glaucoma patients and healthy subjects by using optical coherence tomography angiography
      (OCTA) scans. This novel imaging tool creates three-dimensional angiograms to assesses signal
      changes caused by flowing blood cells in a non-invasive angiogram scan. Blood flow is shown
      as vessel density measured in percentage.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All eyes will undergo imaging to measure blood flow in the back of the eye (retina and optic nerve) using the Avanti AngioVue HD OCTA (optical coherence tomography angiography)</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood flow change in back of eye before and after caffeine</measure>
    <time_frame>Baseline, Hour 1, Hour 2</time_frame>
    <description>Optical Coherence Tomography Angiography (OCTA) will be obtained using the Avanti AngioVue High Definition (HD) OCTA by Optovue. Images will include standard 4.5mm HD disc scan, 6mm HD retina scan, regular optic nerve head (ONH) structural scan, 3D-disc baseline scan and a regular ganglion cell complex analysis (GCCA) structural scan. This will measure blood flow changes in the back of the eye by imaging vessel density in percentage before then 1 and 2 hours after caffeine.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Glaucoma, Primary Open Angle</condition>
  <arm_group>
    <arm_group_label>Glaucoma Patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible participants include patients with mild, moderate or advanced primary open angle glaucoma (POAG) or primary angle closure glaucoma (PACG). Each participant will complete baseline study tasks. Each participant will then receive one 200 mg caffeine tablet to ingest. Study tasks will be performed 1 hour and 2 hours after caffeine ingestion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible participants include healthy subjects with no eye diseases. Each participant will complete baseline study tasks. Each participant will then receive one 200 mg caffeine tablet to ingest. Study tasks will be performed 1 hour and 2 hours after caffeine ingestion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Caffeine tablet</intervention_name>
    <description>Each eligible participant will receive one 200 mg caffeine tablet to ingest after completing all baseline study tasks.</description>
    <arm_group_label>Glaucoma Patients</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 to 90 years

          -  diagnosis of primary open angle glaucoma (Mild, Moderate and Advanced)

          -  healthy subjects with no eye disease

        Exclusion Criteria:

          -  Diseases, ophthalmic or systemic, that are likely to affect OCTA results

          -  greater than moderate cataract

          -  nystagmus

          -  inability to look at target

          -  macular degeneration other than mild drusen or pigmentary changes

          -  diabetic retinopathy

          -  neovascular glaucoma or non-glaucoma optic neuropathies

          -  current macular edema, prior laser to retina, inflammatory retinopathy or
             choroidopathy

          -  keratoconus, corneal ectasia, central corneal scarring

          -  rheumatologic diseases or Raynaud's phenomena

          -  pregnant and lactating women

          -  mental illness or alcohol addiction

          -  pre-existing bladder symptoms, cardiac disease or sleep disorder

          -  refractive spherical diopter greater than 5 or cylinder greater than 3

          -  possible tolerance to caffeine (drinking more than 1 cup coffee per day).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Reza Razeghinejad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wills Eye Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>M. Reza Razeghinejad, MD</last_name>
    <phone>215-928-7023</phone>
    <email>mrazeghi@willseye.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeanne Molineaux, COA</last_name>
    <phone>215-825-4713</phone>
    <email>jmolineaux@gwillseye.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wills Eye Glaucoma Service</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanne Molineaux, COA</last_name>
      <phone>215-825-4713</phone>
      <email>jmolineaux@willseye.org</email>
    </contact>
    <investigator>
      <last_name>Jonathan S Myers, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jay L Katz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marlene R Moster, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael J Pro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Scott Fudemberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anand Montravadi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 5, 2018</study_first_submitted>
  <study_first_submitted_qc>September 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2018</study_first_posted>
  <last_update_submitted>January 31, 2020</last_update_submitted>
  <last_update_submitted_qc>January 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wills Eye</investigator_affiliation>
    <investigator_full_name>M. Reza Razeghinejad MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Primary Open Angle Glaucoma (POAG)</keyword>
  <keyword>Optical Coherence Tomography Angiography (OCTA)</keyword>
  <keyword>Caffeine</keyword>
  <keyword>Macular Blood Flow</keyword>
  <keyword>Peripapillary Blood Flow</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

